Research Towards Developing a Cure for HBV in HIV/HBV Co-Infection (R21 Clinical Trial Not Allowed)

The summary for the Research Towards Developing a Cure for HBV in HIV/HBV Co-Infection (R21 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Research Towards Developing a Cure for HBV in HIV/HBV Co-Infection (R21 Clinical Trial Not Allowed): The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence of human immunodeficiency virus (HIV.

Federal Grant Title:	Research Towards Developing a Cure for HBV in HIV/HBV Co-Infection (R21 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAS-20-121
Type of Funding:	Grant
CFDA Numbers:	93.855
CFDA Descriptions:	Information not provided
Current Application Deadline:	January 7th, 2022
Original Application Deadline:	January 7th, 2022
Posted Date:	March 6th, 2020
Creation Date:	March 6th, 2020
Archive Date:	February 12th, 2022
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	March 6th, 2020

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAS-20-121.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial Not Allowe...; • Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed); • Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 C...; • Nonhuman Primate Reagent Resource (U24 Clinical Trial Not Allowed); • Influenza Transmission Research Consortium (P01 Clinical Trial Optional); • Center for HIV/AIDS Vaccine Immunology (CHAVI); • Genomics of Transplantation Cooperative Research Program; • Asthma and Allergic Diseases Cooperative Research Centers
More Grants from the National Institutes of Health: • Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborat...; • Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required); • Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collab...; • Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clin...; • Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research ...